Oral lactoferrin treatment of experimental oral candidiasis in mice

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 8, 2003, Pages 2619-2623

  Takakura, Natsuko ^a,b   Wakabayashi, Hiroyuki ^a   Ishibashi, Hiroko ^b   Teraguchi, Susumu ^a   Tamura, Yoshitaka ^a   Yamaguchi, Hideyo ^b   Abe, Shigeru ^b  

^a MORINAGA MILK INDUSTRY CO LTD   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LACTOFERRICIN B; LACTOFERRIN; MILK PROTEIN; PEPSIN A; PROTEIN HYDROLYSATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; IMMUNE DEFICIENCY; MOUSE; MOUTH CAVITY; NONHUMAN; PRIORITY JOURNAL; STOMACH INTUBATION; STOMACH TUBE; THRUSH; TONGUE;

ADMINISTRATION, ORAL; ANIMALS; CANDIDIASIS, ORAL; COLONY COUNT, MICROBIAL; FEMALE; INTUBATION, GASTROINTESTINAL; LACTOFERRIN; MICE; MICE, INBRED ICR; PROTEIN HYDROLYSATES; TONGUE;

EID: 0043270528     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.8.2619-2623.2003     Document Type: Article

References (33)

1. Abe, S., T. Okutomi, S. Tansho, H, Ishibashi, H. Wakabayashi, S. Teraguchi, H. Hayasawa, and H. Yamaguchi. 2000. Augmentation by lactoferrin of host defense against Candida infection in mice, p. 195-201. In K. Shimazaki, H. Tsuda, M. Tomita, T. Kuwata, and J. P. Perraudin (ed.), Proceedings of the 4th International Conference on Lactoferrin: structure, function and applications. Elsevier Science B.V., Amsterdam, The Netherlands.
2. Allen, C. M. 1994. Animal models of oral candidiasis. A review. Oral Surg. Oral Med. Oral Pathol. 78:216-221.
3. Bellamy, W., M. Takase, K. Yamauchi, H. Wakabayashi, K. Kawase, and M. Tomita. 1992. Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta 1121:130-136.
4. Bellamy, W., H. Wakabayashi, M. Takase, K. Kawase, S. Shimamura, and M. Tomita. 1993. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med. Microbiol. Immunol. (Berlin) 182:97-105.
5. Bhimani, R. S., Y. Vendrov, and P. Furmanski. 1999. Influence of lactoferrin feeding and injection against systemic staphylococcal infections in mice. J. Appl. Microbiol. 86:135-144.
6. Brock, J. 1995. Lactoferrin: a multifunctional immunoregulatory protein? Immunol. Today 16:417-419.
7. Haversen, L. A., L. Engberg, L. Baltzer, G. Dolphin, L. A. Hanson, and L. Mattsby-Baltzer. 2000. Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice. Infect. Immun. 68:5816-5823.
8. Hermann, P., Z. Berek, G. Nagy, K. Kamotsay, and F. Rozgonyi. 2001. Pathogenesis, microbiological and clinical aspects of oral candidiasis (candidosis). Acta Microbiol. Immunol. Hung. 48:479-495.
9. Jorge, A. O., M. A. Totti, O. P. de Almeida, and C. Scully. 1993. Effect of sialoadenectomy on the carriage of Candida albicans in the mouths of rats. J. Oral Pathol. Med. 22:138-140.
10. Kuhara, T., M. Iigo, T. Itoh, Y. Ushida, K. Sekine, N. Terada, H. Okamura, and H. Tsuda. 2000. Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr. Cancer 38:192-199.
11. Kuipers, M. E., L. Beljaars, N. Van Beek, H. G. De Vries, J. Heegsma, J. J. Van Den Berg, D. K. Meijer, and P. J. Swart. 2002. Conditions influencing the in vitro antifungal activity of lactoferrin combined with antimycotics against clinical isolates of Candida. Impact on the development of buccal preparations of lactoferrin. APMIS 110:290-298.
12. Lockhart, S. R., S. Joly, K. Vargas, J. Swails-Wenger, L. Enger, and D. R. Soll. 1999. Natural defenses against Candida colonization breakdown in the oral cavities of the elderly. J. Dent. Res. 78:857-868.
13. Lopez-Ribot, J. L., R. K. McAtee, S. Perea, W. R. Kirkpatrick, M. G. Rinaldi, and T. F. Patterson. 1999. Multiple resistant phenotypes of Candida albicans coexist during episodes of oropharyngeal candidiasis in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 43:1621-1630.
14. Maebashi, K., T. Itoyama, K. Uchida, N. Suegara, and H. Yamaguchi. 1994. A novel model of cutaneous candidiasis produced in prednisolone-treated guinea-pigs. J. Med. Vet. Mycol. 32:349-359.
15. Masci, J. R. 2000. Complete response of severe, refractory oral candidiasis to mouthwash containing lactoferrin and lysozyme. AIDS 14:2403-2404.
16. Meitner, S. W., W. H. Bowen, and C. G. Haidaris. 1990. Oral and esophageal Candida albicans infection in hyposalivatory rats. Infect. Immun. 58:2228-2236.
17. Munro, C. A., and B. Hube. 2002. Anti-fungal therapy at the HAART of viral therapy. Trends Microbiol. 10:173-177.
18. Nakajima, M. 1999. Oral administration of lactoferrin enhances the productions of IFN-γ and IL-10 in spleen cells cultured with concanavalin A or lipopolysaccharide. Biomed. Res. 20:27-33.
19. National Committee for Clinical Laboratory Standards. 1992. Reference method for broth dilution antifungal susceptibility testing for yeasts. Proposed standard. Document M27-P. National Committee for Clinical Laboratory Standards, Villanova, Pa.
20. Odds, F. C. 1988. Candidiosis of the oropharynx, p. 117-123. In Candida and candidosis: a review and bibliography. Bailliere Tindale, London, United Kingdom.
21. Samaranayake, Y. H., and L. P. Samaranayake. 2001. Experimental oral candidiasis in animal models. Clin. Microbiol. Rev. 14:398-429.
22. Sato, R., O. Inanami, Y. Tanaka, M. Takase, and Y. Naito. 1996. Oral administration of bovine lactoferrin for treatment of intractable stomatitis in feline immunodeficiency virus (FIV)-positive and FIV-negative cats. Am. J. Vet. Res. 57:1443-1446.
23. Sekine, K., Y. Ushida, T. Kuhara, M. Iigo, H. Baba-Toriyama, M. A. Moore, M. Murakoshi, Y. Satomi, H. Nishino, T. Kakizoe, and H. Tsuda. 1997. Inhibition of initiation and early stage development of aberrant crypt foci and enhanced natural killer activity in male rats administered bovine lactoferrin concomitantly with azoxymethane. Cancer Lett. 121:211-216.
24. Soukka, T., J. Tenovuo, and M. Lenander-Lumikari, 1992. Fungicidal effect of human lactoferrin against Candida albicans. FEMS Microbiol. Lett. 69:223-228.
25. Takakura, N., Y. Sato, H. Ishibashi, H. Oshima, K. Uchida, H. Yamaguchi, and S. Abe. A novel murine model of oral candidiasis with local symptoms characteristic of oral thrush. Microbiol. Immunol. 47:321-326.
26. Vorland, L. H. 1999. Lactoferrin: a multifunctional glycoprotein. APMIS 107:971-981.
27. Wakabayashi, H., S. Abe, T. Okutomi, S. Tansho, K. Kawase, and H. Yamaguchi. 1996. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol. Immunol. 40:821-825.
28. Wakabayashi, H., S. Abe, S. Teraguchi, H. Hayasawa, and H. Yamaguchi. 1998. Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob. Agents Chemother. 42:1587-1591.
29. Wakabayashi, H., K. Uchida, K. Yamauchi, S. Teraguchi, H. Hayasawa, and H. Yamaguchi. 2000. Lactoferrin given in food facilitates dermatophytosis cure in guinea pig models. J. Antimicrob. Chemother. 46:595-602.
30. Walsh, T. J., C. E. Gonzalez, S. Piscitelli, J. D. Bacher, J. Peter, R. Torres, D. Shetti, V. Katsov, K. Kligys, and C. A. Lyman. 2000. Correlation between in vitro and in vivo antifungal activities in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. J. Clin. Microbiol. 38:2369-2373.
31. Weinberg, E. D. 1978. Iron and infection. Microbiol. Rev. 42:45-66.
32. Xu, Y. Y., Y. H. Samaranayake, L. P. Samaranayake, and H. Nikawa. 1999. In vitro susceptibility of Candida species to lactoferrin. Med. Mycol. 37:35-41.
33. Yamauchi, K., M. Tomita, T. J. Giehl, and R. T. Ellison, III. 1993. Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect. Immun. 61:719-728.